Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: results from the CHARISMA trial


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1016/j.cjca.2010.12.021

Original Paper URL
http://www.onlinecjc.ca/article/S0828-282X(10)00037-1/abstract

Indexing Status
Subject indexing assigned by NLM

MeSH
Aspirin /therapeutic use; Canada /epidemiology; Cardiovascular Diseases /diagnosis /epidemiology /prevention & control; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors /therapeutic use; Secondary Prevention /economics; Ticlopidine /analogs & derivatives /therapeutic use

AccessionNumber
22011001039

Date bibliographic record published
20/07/2011